Navigation Links
Gene mutations increase risk for aggressive prostate cancer
Date:1/29/2009

January 29, 2009 (BRONX, NY) Men who develop prostate cancer face an increased risk of having an aggressive tumor if they carry a so-called breast cancer gene mutation, scientists from the Albert Einstein College of Medicine of Yeshiva University report in today's issue of Clinical Cancer Research. The findings could help to guide prostate-cancer patients and their physicians in choosing treatment options.

The study, involving 979 men with prostate cancer and 1251 men without the disease, looked at whether participants carried mutations for either of two genes, BRCA1 and BRCA2. Women carrying mutations in either gene face an increased risk of developing breast cancer, ovarian cancer, or both.

All the people enrolled in the Einstein study were of Ashkenazi Jewish descent. The study focused on them because they are five times likelier than people in the general population to carry a mutation of any kind in the BRCA1 or BRCA2 genes. The researchers looked for the presence of three particular mutationstwo in BRCA1 and one in BRCA2. Scientists believe that genetic discoveries among the Ashkenazi can benefit society as a whole in terms of preventing and treating major diseases.

Having any of the three mutations did not increase a man's risk of developing prostate cancer, the study found. But for those men who did develop prostate cancer, two of the mutationsBRCA1-185delAG and the mutated BRCA2 geneincreased the risk that tumors would be aggressive or high-grade, as defined by a Gleason score of 7 or above. The Gleason score, based on the microscopic appearance of prostate tissue removed during a biopsy or surgery, assesses the aggressiveness of a prostate tumor on a scale from 2 (least aggressive) to 10 (most aggressive).

Specifically, prostate cancer patients with high-grade, aggressive tumors (Gleason scores of 7 or above) were 3.2 times more likely to carry the BRCA2 gene mutation than were men in the control group. Carriers of the BRCA1-185delAG mutation were also at increased risk of having an aggressive prostate cancer.

Previous investigations into a possible link between prostate-cancer risk and the BRCA1 and BRCA2 genes have yielded conflicting resultsperhaps because they involved small numbers of subjects and lacked well-matched control groups. "Our large study shows conclusively that prostate cancer patients with either the BRCA2 gene mutation or the BRCA1-185delAG mutation are more susceptible to aggressive cancers than people without that mutation," says Robert Burk, M.D., professor of pediatrics (genetics) at Einstein and senior author of the study.

Routine genetic testing for BRCA mutationsdone by analyzing blood samples or cells swabbed from the inside of one's cheekswouldn't be justified for most men, says Dr. Burk: the prevalence of the mutations in the general population is very low; and men with high Gleason scores already know that their prostate cancer is aggressive. But, notes Dr. Burk, "our findings might have practical implications for some men diagnosed with early-stage (low Gleason score) prostate cancersparticularly Ashkenazi Jewish men, who are much more likely to have these mutations."

"One of the biggest problems with early-stage prostate cancer is being able to distinguish between tumors with the potential to become aggressive and those that may persist for many years without enlarging or spreading," notes Dr. Burk. For that reason, he says, Ashkenazi men diagnosed with early-stage prostate cancer might want to consider getting tested for the BRCA2 and BRCA1-185delAG mutations.

Knowing they have the mutationand that their tumor may become aggressivemay influence treatment options that patients pursue. For example, a prostate cancer patient who has the BRCA2 mutation might vote against 'watchful waiting'in which the growth of the cancer is monitored and treatment is held in abeyanceand instead opt for surgery or radiation treatments with or without hormone blockade therapy.

For early-stage prostate cancer patients in the general population, knowing they carry the BRCA1 or BRCA2 mutation would also be useful, says Dr. Burk. But these mutations are so rare in the general populationa prevalence of far less than one percentthat testing is unlikely to reveal their presence.


'/>"/>

Contact: Michael Heller
mheller@aecom.yu.edu
718-430-4186
Albert Einstein College of Medicine
Source:Eurekalert  

Related medicine news :

1. Yeast mimics severity of mutations leading to fatal childhood illness
2. Mutations common to cancer and developmental disorder examined in a novel disease model
3. Risk of breast cancer mutations underestimated for Asian women, Stanford study shows
4. Genetic Mutations Linked to Deadly Cancers
5. Common Mechanisms May Contribute to Autisms Mutations
6. Migraine mutations reveal clues to biological basis of disorder
7. Specific mutations in the IL2RA gene associated with juvenile idiopathic arthritis
8. Discovery of new family of genetic mutations involved in inflammatory intestinal disease
9. Research program focuses on genetic mutations and cancer risk
10. BRCA Mutations Dont Spot All High-Risk Women
11. Second breast cancer may be greater than thought for high-risk women without BRCA mutations
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene mutations increase risk for aggressive prostate cancer
(Date:5/5/2016)... ... ... CURE Media Group , the nation’s leading digital and print media ... Angels to expand outreach and emotional support for patients of all ages battling ... lifeline to patients and families facing the challenges of cancer diagnosis and treatment,” said ...
(Date:5/5/2016)... ... May 05, 2016 , ... If you don’t mind a bit ... skin, you may want to consider a treatment that some have called the next ... P.C. , Microneedling, also known as skin needling, is a procedure using a ...
(Date:5/5/2016)... ... ... Dermatologic surgeons performed nearly 10 million medically necessary and cosmetic procedures in ... The results of the 2015 ASDS Survey on Dermatologic Procedures released today reveal a ... growing popularity of soft-tissue fillers and body sculpting procedures. , For the fourth ...
(Date:5/5/2016)... ... May 05, 2016 , ... MAP Health Management, LLC, ... that Enlightened Solutions has joined the Premier Outcomes-Driven Provider Network. By becoming a ... their patients being treated for substance use. , Enlightened Solutions was founded by ...
(Date:5/5/2016)... GA (PRWEB) , ... May 05, 2016 , ... Liposuction ... (FDRS) 2016 Conference in St. Louis, Missouri at the Marriot St. Louis Airport Hotel. ... Byrd was chosen to address the conference about her unique specialization in treating Lipedema. ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Actinic Keratosis Market ... to their offering.       (Logo: ... Keratosis Market and Competitive Landscape Highlights 2016, ... products, Actinic Keratosis epidemiology, Actinic Keratosis market ...
(Date:5/3/2016)... , May 4, 2016 ... 154 pages, profiling 09 key companies and supported ... professional and in-depth study on the current state ... overview of the industry including definitions, classifications, applications ... analysis is provided for the international market including ...
(Date:5/3/2016)... May 4, 2016 Research and ... Cancer Stem Cell Therapy Market Outlook 2020" report ... ) , ,Recombinant technology has improved significantly in ... to be developed in coming years. Many cancer drugs ... stem cell therapies are also expected to be developed ...
Breaking Medicine Technology: